Migraine is the most common neurological disorder and severely affects the quality of life of those affected. To prevent chronicity, prophylactic measures are becoming increasingly important in migraine therapy. The principle of the new Calcitonin Gene-Related Peptide (CGRP) antibodies is to start where the pain begins.